Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 35.33 as of 2026-09-26T00:16:11.190Z.
Consensus retrieved: 2026-09-13T23:57:01.194Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-26T00:16:11.190Z.
Quote observation: 2026-09-25T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1455ec06f80d49cd5aa68b705cd80c3aa63adf075df890c399d76f9a88c64272
Forward PE Ratio (35.33) = Dated Quote Price ($72.61) / Consensus Forward EPS ($2.06)
FORWARD PE RATIO
35.33
SECTOR MEDIAN · HEALTHCARE
18.73
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+88.63%
vs the sector median at left
Bio-Techne Corporation
Market Cap
$11.37B
Forward PE Ratio
35.33
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Bio-Techne Corporation (TECH) | $11.37B | 35.33 |
| DaVita Inc. (DVA)vs › | $11.46B | 12.02 |
| Universal Health Services, Inc. (UHS)vs › | $10.83B | 7.94 |
| The Cooper Companies, Inc. (COO)vs › | $10.80B | 12.19 |
| Baxter International Inc. (BAX)vs › | $12.08B | 11.38 |
| Align Technology, Inc. (ALGN)vs › | $10.51B | 13.00 |
| Encompass Health Corporation (EHC)vs › | $12.25B | 20.20 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $10.26B | 39.52 |
| The Ensign Group, Inc. (ENSG)vs › | $10.21B | 22.48 |
| Penumbra, Inc. (PEN)vs › | $12.56B | 67.73 |
Trailing P/E
62.6
reported TTM EPS
Forward P/E
35.3
consensus EPS · fiscal year ending 2027-06-30
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.06 implies +77.6% EPS growth vs the reported trailing $1.16.
At the dated quote price of $72.61, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-06-30 | $2.06 | $1.95 – $2.17 | 8 | 35.3x |
| 2028-06-30 | $2.34 | $2.25 – $2.43 | 5 | 31.0x |
| 2029-06-30 | $2.68 | $2.59 – $2.82 | 1 | 27.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
